new eu rheum survey indic eu humira eros may stabil pt
buyer share believ base new eu
rheumatologist survey humira biosimilar eros meaning appear
less fear recent quarter seen degre stabil
moreov eros project doc indic magnitud may
bad consensu anticip given feedback rais alreadi
above-consensu humira estim ahead consensu
combin promis earli eu rheum feedback rinvoq
prompt us increas ex-u revenu estim see numer
sourc revenu upsid abbv ex-u busi
latest eu rheum check-in humira biosimilar eros pretti meaning recal
earlier year highlight rheum survey field partner
spherix global insight project steeper-than-expect biosimilar eros humira
forward year spherix newest rheum survey field novemb
indic brand humira patient share erod y/i
compar favor eu eros predict doc last year note
recent moder overal ex-u y/i humira eros guidanc
may level encourag less-than-expect eros
also note take place adalimumab class continu
gain patient share y/i potenti soften blow brand humira
moreov though brand humira share fell
eros appear level second half year share stood
think project call brand eros may
overestim
oh btw rinvoq expect strikingli high recal octob
receiv posit chmp opinion rinvoq ra mean eu approv immin
ask project share six month doc indic rinvoq secur
patient share put drug par approv jak well establish
mainstay like enbrel orencia said given eu reimburs dynam
think prudent model gradual eu rinvoq uptak
bottom line increas humira rinvoq estim base feedback
rais ex-u humira revenu estim y/i
bring ww humira revenu estim vs consensu
also increas eu rinvoq estim assum
rinvoq exit eu ra share concurr take valuat
year result new price target
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
spherix
remain buyer share believ base new eu rheumatologist survey
humira biosimilar eros meaning appear less fear least recent
quarter seen degre stabil moreov eros project
doc indic magnitud nearli bad consensu anticip given
feedback increment confid model ww humira revenu ahead
consensu right call fact rais estim slightli combin
promis earli eu rheum feedback rinvoq drive similar increas
rinvoq estim see numer sourc revenu upsid abbv ex-u busi
partner spherix global insight latest eu ra survey field octob
includ feedback rheumatologist countri particip
survey rheumatologist must practic year least ra patient
manag spend least time clinic practic see patient
particip evenli distribut germani franc itali spain uk
averag survey doc ra patient manag mean roughli
patient captur survey
page
biosimilar share
eu humira/adalimumab biosimilar share increas steadili last two year
inde sinc launch biosimilar trend appear acceler share climb
climb see exhibit
contrast overal enbrel/etanercept biosimilar share flat-
downward trend time period vs brand share
cimzia simponi roactemra orencia also trend neg though share
olumi xeljanz grown sinc jak stay flat
trend biolog use
question consid ra patient treat biolog pleas alloc percent patient follow brand
page
eros appear
level
interestingli consist share growth adalimumab render brand humira share larg
flat vs inde eros biosimilar introduct took
place brand humira share fell stand
brand humira ra share lower
recal launch adalimumab biosimilar octob subject ex-u
humira busi direct biosimilar competit begin year manag
guid y/i eros overal ex-u busi assum eros throughout
call novemb manag revis ex-u humira guidanc y/i
eros cite better-than-expect perform area biosimilar impact
market along earlier-than-expect price stabil think share trend shown
exhibit consist commentari
question consid ra patient treat biolog pleas alloc percent patient follow brand
exhibit provid anoth way look current market trend support feedback
exhibit overal adalimumab share grow rheum ask alloc
last five new ra script went adalimumab somewhat higher current
adalimumab share half new adalimumab prescript went biosimilar
total higher current adalimumab biosimilar share reflect momentum
humira biosimilar new script still go brand humira fairli line
current market share
page
new prescript share percent last biologic/smal molecul prescript ra
question think last five new prescript wrote biolog jak ra patient pleas alloc
page
eros
better
eros
look forward rheumatologist project eros brand humira next
six month share declin exhibit biosimilar humira share
project grow time period impli
overal adalimumab share declin would revers trend
adalimumab class growth view project skeptic particularli
consid rheum overestim brand humira share loss spherix report
discuss
even brand humira eros occur compar favor
previou ex-u humira revenu estim y/i one factor lead us
increas ex-u humira estim see
notabl share project rheum expect share loss brand enbrel
share gain etanercept biosimilar notabl growth project approv
jak olumi xeljanz along kevzara
current futur biologic/jak use
question month ra patient treat biolog anticip brand alloc
page
worth
note doc
eros last
highlight one feedback point spherix survey rheum survey april/may
project brand humira share fall repres loss
bp six month recal brand humira share stood
declin mean doc overestim share loss cours
delta like attribut differ pool rheum sampl vs
would still give us paus take heart project survey
likewis call brand humira declin
rheum also overestim jak adopt olumi share well
month project xeljanz share
project project kevzara growth also fail
materi grow well short project share
interestingli though doc overestim brand humira eros jak adopt
fairli accur adalimumab biosimilar project project six
month biosimilar humira share would actual survey indic
biosimilar humira share
current futur biologic/jak use
question month ra patient treat biolog anticip brand alloc
page
share huge
encouragingli survey eu rheum expect strong rinvoq uptak recal chmp issu
posit opinion rinvoq ra octob ema approv expect immin
rheumatologist project meaning uptak rheum least moder rinvoq
familiar ask make six-month share project scenario rinvoq
commerci avail project market share project user base
project share would put rinvoq roughli line xeljanz olumi would mark
expans jak class rinvoq share would come expens tnf
futur biologic/jak use inclus rinvoq
question abbvi upadacitinib becom commerci avail within next six month anticip six month project share chang
page
bump ex-u
humira rinvoq
estim target
given feedback think previou ex-u humira rinvoq revenu estim
low take opportun adjust higher see exhibit
recal rheum project brand humira eros next six month
reason detail think like overestim even level brand
humira eros occur eu would still compar favor previou ex-
us humira revenu estim y/i cours factor play
price account share project could worsen brand humira
eu revenu declin next year even would point biosimilar
introduc eu europ repres ex-u humira busi growth
ex-u geographi outsid europ may somewhat off-set eu eros
take account increas ex-u humira revenu estim
repres y/i eros humira consensu broken
geographi avail make comparison difficult new ww revenu
estim higher ww factset consensu note
ww humira consensu alreadi increas sinc report result
base survey feedback think may room humira estim
increas
mind doc overestim jak growth recent quarter uptak
depend country-by-countri reimburs progress model rheumatologist
feedback call share within commerci avail verbatim howev
previous assum rinvoq would exit eu ra market share
revenu adjust higher model rinvoq exit
market share translat revenu also bring eu market
penetr number out-year respect
even adjust dont model rinvoq achiev eu ra share
howev rapid rinvoq uptak could prove sourc upsid
net ep impact model chang ep estim increas
estim come dont think
consensu estim necessarili compar unclear
estim includ impact allergan acquisit
page
draw close shift valuat year stay
consist valuat methodolog appli multipl non-gaap ep discount
back target increas
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
dollar except per share data
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit shaqe
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
